-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, AAfd1DsyLsGOlG4w6d+97fynfw6BgpNKEdu0ZXahwcwlx+6mZIgC1lEb2DFjTgj7 MpOOG0Qpwi9wucAsmbi8wA== 0001144204-08-062821.txt : 20081112 0001144204-08-062821.hdr.sgml : 20081111 20081112150152 ACCESSION NUMBER: 0001144204-08-062821 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20081107 ITEM INFORMATION: Termination of a Material Definitive Agreement FILED AS OF DATE: 20081112 DATE AS OF CHANGE: 20081112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUNESIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001061027 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943295878 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51531 FILM NUMBER: 081180484 BUSINESS ADDRESS: STREET 1: 395 OYSTER POINT BOULEVARD STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-266-3500 MAIL ADDRESS: STREET 1: 395 OYSTER POINT BOULEVARD STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: MOSAIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19980709 8-K 1 v131707_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 7, 2008

SUNESIS PHARMACEUTICALS, INC.
 
(Exact Name of Registrant as Specified in its Charter)

Delaware
000-51531
94-3295878
(State or Other Jurisdiction
(Commission
(IRS Employer
of Incorporation)
File Number)
Identification No.)

395 Oyster Point Boulevard, Suite 400
South San Francisco, California
94080
(Address of Principal Executive Offices)
(Zip Code)

Registrant’s telephone number, including area code: (650) 266-3500

Not Applicable
(Former Name or Former Address, if Changed Since Last Report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 

Item 1.02. Termination of a Material Definitive Agreement.
 
On November 7, 2008, Sunesis Pharmaceuticals, Inc. (“Sunesis”) agreed to accelerate the payment of its entire outstanding balance under that certain Master Security Agreement, dated as of June 15, 2000, as amended (the “Security Agreement”), by and between Sunesis and General Electric Capital Corporation (“General Electric”). In exchange for Sunesis’ payment of approximately $1.5 million, General Electric agreed to terminate the Security Agreement, related Negative Pledge Agreement, dated May 17, 2002, and outstanding promissory notes with Sunesis. There are no material relationships between Sunesis and General Electric other than in respect of the Security Agreement and the related documents.

Sunesis entered into the Security Agreement in June 2000 for the financing of certain equipment; various credit lines have been issued under the Security Agreement since 2000. Outstanding balances under the credit lines bore interest at rates ranging from 8.70 percent to 10.61 percent per annum due in 36 to 48 monthly payments. The equipment loans under the Security Agreement were secured by the equipment financed.

As part of its 2008 restructuring, Sunesis implemented a corporate realignment to focus on the development of its oncology products and terminated its research activities. Due to this realignment, certain laboratory equipment is currently being held-for-sale. Sunesis was required to pay the entire outstanding balance under the Security Agreement with General Electric before it could sell the held-for-sale assets.

* * * * * * * * *
 
 
 
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
SUNESIS PHARMACEUTICALS, INC.
 
 
 
 
 
 
Dated: November 12, 2008
By:  
/s/ Valerie L. Pierce
 
 
Valerie L. Pierce
 
Senior Vice President, General Counsel and Corporate Secretary
  
 
 
 
 -----END PRIVACY-ENHANCED MESSAGE-----